Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

Harrison Simon J.; Mainwaring Paul; Price Timothy; Millward Michael J.; Padrik Peeter; Underhill Craig R.; Cannell Paul K.; Reich Steven D.; Trikha Mohit; Spencer Andrew

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

【24h】

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

机译：Marizomib（NPI-0052）在包括多发性骨髓瘤在内的晚期恶性肿瘤患者中进行的I期临床试验：研究NPI-0052-102最终结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors.

机译：目的：Marizomib（NPI-0052）是一种不可逆的蛋白酶体抑制剂，衍生自海洋放线菌，具有与其他蛋白酶体抑制剂不同的活性和特异性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第18期|共8页
作者
Harrison Simon J.; Mainwaring Paul; Price Timothy; Millward Michael J.; Padrik Peeter; Underhill Craig R.; Cannell Paul K.; Reich Steven D.; Trikha Mohit; Spencer Andrew;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results [J] . Harrison Simon J., Mainwaring Paul, Price Timothy, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第18期

机译：Marizomib（NPI-0052）在包括多发性骨髓瘤在内的晚期恶性肿瘤患者中进行的I期临床试验：研究NPI-0052-102最终结果
2. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results [J] . Spencer Andrew, Harrison Simon, Zonder Jeffrey, British Journal of Haematology . 2018,第1期

机译：在复发和难治多骨髓瘤（NPI-0052-107）中评估Marizomib，Pomalidomide和低剂量地塞米松的第1阶段临床试验（NPI-0052-107）：最终的研究结果
3. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials [J] . Knauf Wolfgang, Aldaoud Ali, Losem Christoph, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2018,第期

机译：Lenalidomide加上患有复发或难治性多发性骨髓瘤的患者的地塞米松：与关键阶段3临床试验的非介入研究和比较的最终结果
4. TREATING MULTIPLE MYELOMA IN A CLINICAL TRIAL [C] . Annual Conference of the Veterinary Cancer Society. . 2017

机译：在临床试验中治疗多发性骨髓瘤
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial [O] . Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen, -1

机译：ABCB1单核苷酸多态性对多发性骨髓瘤患者来那度胺治疗结果的影响的药物遗传学研究：IV期观察性研究和随后的II期临床试验的结果
7. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results [O] . Simon J. Harrison, Paul Mainwaring, Timothy Price, 2016

机译：Marizomib（NPI-0052）临床试验在患有多发性骨髓瘤的晚期恶性肿瘤患者中的临床试验：研究NPI-0052-102最终结果

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

摘要

著录项

相似文献

相关主题

期刊订阅